Ernest Robert De Paolantonio - Oct 4, 2022 Form 4/A - Amendment Insider Report for Journey Medical Corp (DERM)

Role
Officer
Signature
/s/ Ramsey Alloush, attorney-in-fact
Stock symbol
DERM
Transactions as of
Oct 4, 2022
Transactions value $
-$24,324
Form type
4/A - Amendment
Date filed
3/1/2023, 08:46 PM
Date Of Original Report
Oct 6, 2022
Previous filing
Jul 25, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DERM Common Stock, par value $0.0001 per share Sale -$24.3K -10.1K -3.74% $2.41 260K Oct 4, 2022 Direct F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Ernest Robert De Paolantonio is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 In connection with the vesting of 40,000 shares on October 1, 2022, a total of 10,093 of such shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.
F2 Due to a clerical error, the original Form 4 filed on October 6, 2022 reflected an acquisition of 10,029 shares in lieu of a disposition of 10,029 shares. The amount of securities beneficially owned following the reported transaction reported in the previously filed Form 4 is correct.
F3 Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on October 4, 2022, was $2.38 to $2.43. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares sold at each separate price.
F4 Includes restricted stock units, which vest over various time periods.

Remarks:

As of the date of the original Form 4 filed on October 6, 2022, the Reporting Person was the Chief Financial Officer of the Issuer. In a Current Report on Form 8-K filed by the Issuer with the Securities and Exchange Commission on January 20, 2023, the Issuer announced that the Reporting Person provided notice of his resignation to the Issuer on January 16, 2023 and, as such, is no longer a Section 16 filer as of the date of this amendment.